Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
P/E ratio for Allakos Inc. (ALLK)
P/E ratio as of 2023: -1.28
According to Allakos Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.28. At the end of 2022 the company had a P/E ratio of -1.68.
P/E ratio history for Allakos Inc. from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.28 |
| 2022 | -1.68 |
| 2021 | -1.97 |
| 2020 | -46.94 |
| 2019 | -55.49 |
| 2018 | -23.81 |
| 2017 | -43.78 |
| 2016 | -60.30 |